Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500682 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Thomas P Corner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield …. Hauptthemen laut MEDLINE: Jumonji Domain-Containing Histone Demethylases, Enzyme Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Wellcome Trust, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
The human 2‐oxoglutarate‐dependent oxygenase Jumonji‐C domain‐containing protein 6 (JMJD6) catalyzes post‐translational C‐5 lysyl residue hydroxylation in multiple proteins. Aberrant JMJD6 catalysis is associated with the upregulation of androgen receptor splice variant 7 (AR‐V7), which confers resistance towards antiandrogens used for prostate cancer treatment; JMJD6 is thus a promising cancer target. To date, few small‐molecule JMJD6 inhibitors are reported, likely in part reflecting a lack of robust assays to monitor effects of small molecules on catalysis by isolated JMJD6. The use of solid‐phase extraction coupled to mass spectrometry assays is described to screen scaffolds for the development of selective JMJD6 inhibitors. The results reveal that the reported JMJD6 inhibitors WL12, SKLB325, and Compound 7p manifest relatively inefficient JMJD6 inhibition in vitro. By contrast, some, but not all, clinically used inhibitors of the human hypoxia‐inducible factor‐α prolyl hydroxylase domain‐containing proteins (PHDs) efficiently inhibit isolated JMJD6, in particular Enarodustat and Desidustat. The results identify attractive scaffolds for the development of selective, cell permeable JMJD6 inhibitors and suggest that JMJD6 inhibition is a potential off‐target effect of PHD inhibitors in clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.
ORCID-Profile: Lennart Brewitz, Christopher J Schofield
Förderung
- Cancer Research UK
- Wellcome Trust
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Corner, T. P., Salah, E., Tumber, A., Holt-Martyn, J. P., Brewitz, L., & Schofield, C. J. (2025). Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6. ChemMedChem. https://doi.org/10.1002/cmdc.202500682
Vancouver
Corner TP, Salah E, Tumber A, Holt-Martyn JP, Brewitz L, Schofield CJ. Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6. ChemMedChem. 2025. doi:10.1002/cmdc.202500682
BibTeX
@article{Corner2025,
author = {Corner, Thomas P and Salah, Eidarus and Tumber, Anthony and Holt-Martyn, James P and Brewitz, Lennart and Schofield, Christopher J},
title = {Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500682}
}
EUVIMED